Route 92 Medical, Inc.
$9.7M 774 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Dermavant Sciences, Inc.
Dermavant Sciences, Inc. reported $9,686,583.27 across General Payments, Research, and Ownership to 73,486 physicians and teaching hospitals across 89,827 transactions.
- $9.7M
- All-tracks total
- 89,827
- Transactions
- 73,486
- Recipients
- +$115.0K
- General Payments vs PY2023
Dermavant Sciences, Inc. reported $9,686,583.27 across all CMS Open Payments tracks (General + Research + Ownership) to 73,486 physicians and teaching hospitals in Program Year 2024 - ranking #179 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $6,652,770.38, averaging $131.82 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer dermavant-sciences-inc Dermavant Sciences, Inc.
$9.7M · #179/1,925 · 0.1% industry · PY2024
- TOT $9.7M
- RANK #179
- SHARE 0.1%
- TXN 89,827
- RCP 73,486
- CAT 6
- GEN $6.7M
- ΔGEN +$115.0K
- TOP1 4.9%
- PY 2024
Volume peers
Nearest volume peer: Route 92 Medical, Inc. ($9.7M)
Dermavant Sciences, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Dermavant Sciences, Inc.'s CMS-reported General Payments increased by $115.0K (+1.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: DERMAVANT SCIENCES, INC.PY2023: DERMAVANT SCIENCES, INC.PY2024: Dermavant Sciences, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $6,537,745.85
- PY2024
- $6,652,770.38
What the Data Shows for Dermavant Sciences, Inc.
In Program Year 2024, Dermavant Sciences, Inc. reported $9,686,583.27 in payments to 73,486 physicians and teaching hospitals across 89,827 individual transactions, an average of $107.84 per transaction and $131.82 per recipient. That total places Dermavant Sciences, Inc. at rank #179 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.1% slice of all industry payments reported nationwide for the year.
"Compensation for Services Other Than Consulting" leads the 6-category general-payment breakdown below at $2.4M (35.7% of General Payments, 1,068 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Dermavant Sciences, Inc.'s 6-category general-payment breakdown at $2.4M, 35.7% of the reported total.
Dermavant Sciences, Inc. reports 6 general-payment categories - the top three are Compensation for Services Other Than Consulting (35.7%), Consulting Fee (33.5%), and Food and Beverage (22.8%). The remaining 3 categories make up 8.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Dermavant Sciences, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $2.4M | 1,068 | 35.7% |
| Consulting Fee | $2.2M | 511 | 33.5% |
| Food and Beverage | $1.5M | 70,888 | 22.8% |
| Travel and Lodging | $377.1K | 990 | 5.7% |
| Grant | $151.1K | 1 | 2.3% |
| Education | $3.6K | 28 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $750,382.19 (11.3%) of $6,652,770.38 in this company's General Payments records across 10,482 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Dermavant Sciences, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
National Jewish Health
$323,050.00 across 4 reported transactions
- 2
George Lewitt
$123,192.80 across 97 reported transactions
- 3
Alexandra Golant
$113,487.41 across 94 reported transactions
- 4
Naiem Issa
$100,248.14 across 131 reported transactions
- 5
Cory Rubin
$90,403.84 across 52 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Dermavant Sciences, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Dermavant Sciences, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Dermavant Sciences, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
EyePoint Pharmaceuticals US, Inc.
$9.7M 748 recipients
Compare payment profiles
Supernus Pharmaceuticals, Inc.
$9.7M 61,253 recipients
Compare payment profiles
H. Lundbeck A S
$9.8M 303 recipients
Compare payment profiles
W. L. Gore & Associates, Inc.
$9.5M 25,860 recipients
Compare payment profiles
Applied Medical Research, Inc
$10.0M 0 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.